| Drug name | Target | Type of antibody | Indications |
| Nivolumab | PD-1 | IgG4 | Metastatic melanoma, adjuvant treatment of melanoma, metastatic non-small cell lung cancer, classical Hodgkin’s lymphoma, renal cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, urethral cancer, bladder cancer, mismatch repair defect colon cancer |
| Pembrolizumab | PD-1 | IgG4 | Highly microsatellite unstable tumors, melanoma, non-small cell lung cancer, classic Hodgkin’s lymphoma, head and neck squamous cell carcinoma, urethral cancer, gastric cancer |
| Atezolizumab | PD-L1 | IgG1 | Advanced bladder cancer, metastatic non-small cell lung cancer, locally advanced or metastatic urethral cancer |
| Durvalumab | PD-L1 | IgG1 | Locally advanced or metastatic urethral cancer |
| Avelumab | PD-L1 | IgG1 | Locally advanced or metastatic urethral cancer, metastatic Merkel cell carcinoma in adolescents and adults |